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1007-174 Clopidogrel Regulates Platelet, Leukocyte, and 
Endothelial Interactions in Type 2 Diabetes Mellitus
Jaydeep Sarma, Scott A. Harding, Jehangir Din, Paul Macioca, David E. Newby, Keith A. 
A. Fox, University of Edinburgh, Edinburgh, United Kingdom
Introduction
Patients with diabetes mellitus have an increased risk of developing atherosclerosis and
its sequelae. Atherosclerosis is now recognized to be an inflammatory disease involving
multiple interactions between platelets, leukocytes and endothelial cells. We examined
whether specific platelet ADP receptor inhibition with the thienopyridine clopidogrel
reduced platelet-monocyte binding, monocyte activation and endothelial activation, in
patients with type 2 diabetes mellitus.
Methods
Twenty patients with type 2 diabetes mellitus received clopidogrel 75mg daily for 28 days.
Platelet surface P-selectin and CD40L ligand (CD40L) expression, monocyte surface
CD40 and CD11b expression, platelet-monocyte binding (PMB) and platelet-neutrophil
binding (PNB) were assessed by flow cytometry; plasma soluble (s)CD40L and soluble
(s)E-selectin were assessed by ELISA; the chemokines RANTES and MCP-1 were
assessed by flow cytometric bead array, before and after treatment.
Results
Significant reductions were seen in platelet surface P-Selectin (p=0.002), PMB (p=0.007)
and PNB (p=0.0025), and also monocyte surface CD40 (p=0.007) and CD11b
(p=0.0245) after clopidogrel treatment. No significant changes occurred in platelet sur-
face CD40L (p=0.61), nor in plasma levels of sCD40L (p=0.24), sE-selectin (p=0.44) and
MCP-1 (p=0.8175), but there was a highly significant reduction in plasma RANTES,
(p<0.0001).
Conclusions
Clopidogrel acts to reduce platelet and leukocyte activation and adhesion in type II Dia-
betes Mellitus, suggesting a potential anti-inflammatory effect of thienopyridines. The
lack of change in sE-selectin and the specific reduction in the platelet-derived chemokine
RANTES suggests that these effects are platelet-driven, and not due to altered endothe-
lial function.
1007-175 Antithrombotic Effects of Angiotensin II Receptor 
Blockade
David A. Vorchheimer, Mohammad Urooj Zafar, Anuragini Pandey, Ida C. Guzman, Jose 
Rodriguez, Bharathi Reddy, Mitchell A. Cohen, Juan J. Badimon, Mount Sinai Medical 
Center, New York, NY, AstraZeneca LLP, Wilmington, DE
Background: Angiotensin II accelerates the development and progression of athero-
thrombosis. Treatment with angiotensin receptor blockers (ARB) can reverse endothelial
dysfunction, reduce oxidant stress, and inhibit inflammation. Recent large clinical trials
demonstrate that ARB therapy can slow or prevent the progression of coronary artery
disease. The clinical benefits observed in these trials suggested benefit beyond blood
pressure reduction, perhaps via alternate mechanisms. Methods: We used the Badimon
perfusion chamber to study the effects of a selective angiotensin II type 1 receptor antag-
onist (candesartan) on platelet-vessel wall interaction in 23 patients with cardiovascular
disease. Thrombus formation was assessed at low (212/s) and high (1690/s) shear rates,
which mimic the rheologic conditions seen in venous blood and mildly stenotic coronary
arteries. Thrombus formation was measured before and after 6 weeks treatment with
candesartan (16mg/day) in addition to other standard treatments for CAD. Results:
Baseline demographic features of the population included age 61+11years, 48% males,
with the following CAD risk factors: 78% had hypertension, 52% had diabetes, and 91%
had hyperlipidemia. Candesartan reduced systolic (133+20 to 115+12 mm Hg) and dias-
tolic (80+10 to 75+8 mm Hg) blood pressure. Thrombus formation was reduced from
2644+231 to 1960+224 µ/mm2 (∆ =26.5%, p<0.001) at low shear rate, and from
7756+552 to 5502+394 µ/mm2 (∆= 27.5%, p<0.001) at high shear rate. However, there
was no correlation between inhibition of thrombus formation and systolic (r=0.218) or
diastolic (r=0.076) blood pressure reduction. Conclusion: Short-term ARB treatment sig-
nificantly reduced platelet-thrombus formation in patients with cardiovascular disease.
This antithrombotic effect appeared to be independent of blood pressure reduction.
Ongoing clinical trials will determine whether this antithrombotic effect will translate into
clinical benefits of ARB therapy for post MI patients.
1007-176 Peroxisome Proliferator Activated Receptor Gamma 
Agonist Protects Against Arterial Thrombosis in a 
Mouse Model of Insulin Resistance
Peter F. Bodary, Fernando B. Vargas, Susan Davis King, Michael T. Purkey, Kevin J. 
Wickenheiser, Daniel T. Eitzman, University of Michigan, Ann Arbor, MI
Background The prevalence of insulin resistance and diabetes is increasing in the U.S.
Both insulin resistance and diabetes are associated with a marked increase in cardiovas-
cular disease mortality although the mechanisms responsible for this increased risk are
largely unknown. Since thrombosis occurring at sites of vascular disease accounts for
the vast majority of cardiovascular complications in insulin resistant patients, we hypothe-
sized that directly improving insulin sensitivity with a peroxisome proliferator activitated
receptor gamma (PPARγ) agonist may be effective in reducing the thrombotic response
following vascular injury. Methods and Results. A model of obesity and insulin resis-
tance was used that involved feeding mice of the KK strain a high fat diet for 2 weeks
(n=12). Mice were then provided standard rodent chow and divided into two groups to
receive either pioglitazone (a synthetic PPARγ ligand, 0.012% food admixture) (n=5) or
placebo (n=7). Mice receiving the pioglitazone had significantly reduced fasting plasma
glucose, leptin, insulin and triglyceride levels with increased adiponectin concentrations
after 2.5 weeks of treatment. To determine if pioglitazone treatment was associated with
a beneficial effect on thrombosis following vascular injury, mice were subjected to photo-
chemical injury of the carotid artery. Mice receiving placebo formed an occlusive throm-
bus 11.3 + 1.0 minutes following the initiation of injury while mice receiving pioglitazone
formed an occlusive thrombus in 22.3 + 3.9 minutes (p<0.05). No effect of pioglitazone
was observed in euglycemic C57BL/6 mice (n=4 per group) suggesting that the benefi-
cial effect of pioglitazone requires pre-existing insulin resistance. Conclusion. The
PPARγ agonist pioglitazone provides protection against thrombosis in a mouse model of
obesity and insulin resistance.
1007-177 Predictors of Major Hemorrhage Following Initiation of 
Warfarin Therapy
Henock Saint-Jacques, Anne S. Hellkamp, David E. Kandzari, Christopher M. O' Connor, 
Robert Daly, Stephen L. Kopecky, Anatoly Langer, David Vorchheimer, Patrick T. O' Gara, 
Valentin Fuster, Robert M. Califf, Robert A. Harrington, Duke Clinical Research Institute, 
Duke University Medical Center, Durham, NC
Background: Despite documented benefits of oral anticoagulant therapy for patients
(pts) at risk for embolic events, use of warfarin remains low mostly secondary to concerns
for major hemorrhage (MH). Objective: We identified pts characteristics that predict MH
after initiation of a uniform dosing of warfarin. Methods: Among pts in the Coumadin
Aspirin Reinfarction Study (CARS) who were randomized to a daily fixed dose of warfarin
3mg combined with aspirin 80 mg, INR levels were measured at the end of the first week
of therapy by a core laboratory using the same thromboplastin reagent (ISI=0.97). MH
was defined as intracranial hemorrhage or spontaneous bleeding that required surgical
intervention, a decrease in hemoglobin > 2 g/dL or sufficient to require transfusion, or
bleeding that contributed to death, impaired sight or hearing. Multivariable Cox propor-
tional hazard model was developed to assess the relationship between baseline pts char-
acteristics and MH. Results: MH occured among 64 out of 2,913 pts over median
(25th,75th percentile) = 151(51, 340) days after initiation of therapy. MH was associated
with increasing age, non-white ethnicity, higher INR levels or BMI, and use of adrenergic
agents. Concomitant use of beta blockers had a protective effect. Conclusion: These
data identify important pts characteristics that are predictive of warfarin-associated MH.
Clinicians are encouraged to account for these modifiable risk factors and identify high-
risk groups when initiating warfarin therapy.
1007-178 Elevated Levels of Hemostatic Markers in Patients With 
Atrial Fibrillation and Aortic Atherosclerosis
Keiko Nakagawa, Tadakazu Hirai, Tomoki Kameyama, Noriko Shinokawa, Hidetsugu 
Asanoi, Hiroshi Inoue, Toyama Medical and Pharmaceutical University, Toyama, Japan
Background: Patients (pts) with atrial fibrillation (AF) are at risk for thromboembolism,
and their prothrombotic profiles might be associated with coexistent cardiovascular dis-
ease, rather than AF alone.
Methods: In 63 pts with AF and 42 pts with normal sinus rhythm (NSR) who underwent
transesophageal echocardiography, plasma levels of markers for platelet activity (β-
thromboglobulin and platelet factor 4), thrombotic status (thrombin-antithrombin III com-
plex (TAT) and prothrombin fragment F1+2 (F1+2)) and fibrinolytic status (plasmin-α2-
plasmin inhibitor complex and D-dimer) were determined. Thromboembolic risk and
severity of aortic atherosclerosis were evaluated by transesophageal echocardiography.
Results: Pts with AF, as a whole, had higher hemostatic markers and severe left atrial
spontaneous contrast than those in NSR. F1+2 and fibrinolytic markers in pts with severe
atherosclerosis (atheroma > 5mm and/or mobile plaque) were significantly elevated as
compared with that of pts without severe atheroma. Particularly, AF pts with severe ath-
erosclerosis showed significantly higher levels of F1+2 and fibrinolytic markers than in
those without atherosclerosis, while markers for platelet activity were not significantly dif-
ferent between AF pts with and without severe atherosclerosis (Figure). Conclusion: Pts
with severe aortic atherosclerosis coexistent with AF appear to have an increased risk for
thromboembolism, and could benefit from more intensive antithrombotic therapy.
Predictors of major hemorrhage among 2913 patients following initiation of warfarin 
therapy.
Variables P-value HR ( 95% CI)
Age 0.0001 1.32 (1.17, 1.50) for 5 years increase
INR 0.0001 1.15 (1.07, 1.23) for 0.5 unit increase
Beta blockers use 0.002 0.45 (0.27, 0.74)
Non-white race 0.006 2.29 (1.26, 4.16)
BMI 0.051 1.05 (1.00, 1.09) for each unit increase
Adrenergic agents use 0.061 2.31 (0.96, 5.52)
